Does the media refer more to DYAI or COYA?

In the previous week, Dyadic International had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.94 beat Dyadic International's score of 0.57 indicating that Coya Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Coya Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer PYXS or DYAI?

In the previous week, Dyadic International had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Dyadic International and 3 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.62 beat Dyadic International's score of 0.57 indicating that Pyxis Oncology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pyxis Oncology 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend CUE or DYAI?

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 274.53%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Cue Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cue Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Dyadic International 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33

Does the media prefer CGTX or DYAI?

In the previous week, Cognition Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 6 mentions for Cognition Therapeutics and 4 mentions for Dyadic International. Cognition Therapeutics' average media sentiment score of 1.04 beat Dyadic International's score of 0.57 indicating that Cognition Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cognition Therapeutics 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Dyadic International 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings and valuation, DYAI or PLYX?

Polaryx Therapeutics has lower revenue, but higher earnings than Dyadic International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Dyadic International $3.09M 9.45 -$7.36M -$0.23 N/A Polaryx Therapeutics N/A N/A N/A N/A N/A

Dyadic International (DYAI) Competitors

$0.80 +0.06 (+8.10%)

Closing price 06/26/2026 04:00 PM Eastern

Extended Trading

$0.82 +0.02 (+2.37%)

As of 06/26/2026 07:59 PM Eastern

Compare

DYAI vs. COYA, PYXS, CUE, CGTX, and PLYX

Should you buy Dyadic International stock or one of its competitors? MarketBeat compares Dyadic International with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Dyadic International include Coya Therapeutics (COYA), Pyxis Oncology (PYXS), Cue Biopharma (CUE), Cognition Therapeutics (CGTX), and Polaryx Therapeutics (PLYX). These companies are all part of the "pharmaceutical products" industry.

How does Dyadic International compare to Coya Therapeutics?

Dyadic International (NASDAQ:DYAI) and Coya Therapeutics (NASDAQ:COYA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, profitability, dividends, analyst recommendations, earnings, institutional ownership, media sentiment and risk.

In the previous week, Dyadic International had 2 more articles in the media than Coya Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 2 mentions for Coya Therapeutics. Coya Therapeutics' average media sentiment score of 0.94 beat Dyadic International's score of 0.57 indicating that Coya Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Coya Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

28.0% of Dyadic International shares are owned by institutional investors. Comparatively, 39.8% of Coya Therapeutics shares are owned by institutional investors. 20.9% of Dyadic International shares are owned by insiders. Comparatively, 6.1% of Coya Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Dyadic International has a net margin of -192.40% compared to Coya Therapeutics' net margin of -266.10%. Coya Therapeutics' return on equity of -55.86% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Coya Therapeutics	-266.10%	-55.86%	-48.86%

Dyadic International presently has a consensus target price of $3.00, suggesting a potential upside of 274.53%. Coya Therapeutics has a consensus target price of $15.33, suggesting a potential upside of 178.79%. Given Dyadic International's higher probable upside, equities analysts plainly believe Dyadic International is more favorable than Coya Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Coya Therapeutics	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71

Dyadic International has a beta of 1.17, meaning that its share price is 17% more volatile than the broader market. Comparatively, Coya Therapeutics has a beta of 0.62, meaning that its share price is 38% less volatile than the broader market.

Dyadic International has higher earnings, but lower revenue than Coya Therapeutics. Coya Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	9.45	-$7.36M	-$0.23	N/A
Coya Therapeutics	$7.95M	16.23	-$21.23M	-$1.15	N/A

Summary

Dyadic International and Coya Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Pyxis Oncology?

Pyxis Oncology (NASDAQ:PYXS) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, media sentiment, valuation, institutional ownership, earnings and analyst recommendations.

In the previous week, Dyadic International had 1 more articles in the media than Pyxis Oncology. MarketBeat recorded 4 mentions for Dyadic International and 3 mentions for Pyxis Oncology. Pyxis Oncology's average media sentiment score of 0.62 beat Dyadic International's score of 0.57 indicating that Pyxis Oncology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pyxis Oncology	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Pyxis Oncology currently has a consensus target price of $6.83, indicating a potential upside of 146.69%. Dyadic International has a consensus target price of $3.00, indicating a potential upside of 274.53%. Given Dyadic International's higher probable upside, analysts clearly believe Dyadic International is more favorable than Pyxis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pyxis Oncology	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Pyxis Oncology has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Pyxis Oncology's return on equity of -135.60% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pyxis Oncology	N/A	-135.60%	-85.00%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Pyxis Oncology has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

39.1% of Pyxis Oncology shares are owned by institutional investors. Comparatively, 28.0% of Dyadic International shares are owned by institutional investors. 5.7% of Pyxis Oncology shares are owned by insiders. Comparatively, 20.9% of Dyadic International shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Dyadic International has lower revenue, but higher earnings than Pyxis Oncology. Dyadic International is trading at a lower price-to-earnings ratio than Pyxis Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pyxis Oncology	$13.86M	12.66	-$79.62M	-$1.31	N/A
Dyadic International	$3.09M	9.45	-$7.36M	-$0.23	N/A

Summary

Pyxis Oncology beats Dyadic International on 10 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Cue Biopharma?

Cue Biopharma (NASDAQ:CUE) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

35.0% of Cue Biopharma shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 14.6% of Cue Biopharma shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 274.53%. Given Dyadic International's stronger consensus rating and higher possible upside, analysts clearly believe Dyadic International is more favorable than Cue Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cue Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Dyadic International has lower revenue, but higher earnings than Cue Biopharma. Cue Biopharma is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cue Biopharma	$27.47M	3.88	-$26.60M	-$5.58	N/A
Dyadic International	$3.09M	9.45	-$7.36M	-$0.23	N/A

In the previous week, Dyadic International had 3 more articles in the media than Cue Biopharma. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for Cue Biopharma. Cue Biopharma's average media sentiment score of 1.89 beat Dyadic International's score of 0.57 indicating that Cue Biopharma is being referred to more favorably in the media.

Company	Overall Sentiment
Cue Biopharma	Very Positive
Dyadic International	Positive

Cue Biopharma has a net margin of -59.65% compared to Dyadic International's net margin of -192.40%. Cue Biopharma's return on equity of -98.30% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cue Biopharma	-59.65%	-98.30%	-53.69%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Cue Biopharma has a beta of 2.52, suggesting that its stock price is 152% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, suggesting that its stock price is 17% more volatile than the broader market.

Summary

Dyadic International beats Cue Biopharma on 9 of the 16 factors compared between the two stocks.

How does Dyadic International compare to Cognition Therapeutics?

Cognition Therapeutics (NASDAQ:CGTX) and Dyadic International (NASDAQ:DYAI) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, media sentiment, dividends, valuation, risk, institutional ownership, analyst recommendations and earnings.

43.4% of Cognition Therapeutics shares are held by institutional investors. Comparatively, 28.0% of Dyadic International shares are held by institutional investors. 11.1% of Cognition Therapeutics shares are held by company insiders. Comparatively, 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Cognition Therapeutics had 2 more articles in the media than Dyadic International. MarketBeat recorded 6 mentions for Cognition Therapeutics and 4 mentions for Dyadic International. Cognition Therapeutics' average media sentiment score of 1.04 beat Dyadic International's score of 0.57 indicating that Cognition Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cognition Therapeutics	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Dyadic International	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Dyadic International has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than Dyadic International, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cognition Therapeutics	N/A	N/A	-$23.49M	-$0.24	N/A
Dyadic International	$3.09M	9.45	-$7.36M	-$0.23	N/A

Cognition Therapeutics has a beta of 1.75, meaning that its stock price is 75% more volatile than the broader market. Comparatively, Dyadic International has a beta of 1.17, meaning that its stock price is 17% more volatile than the broader market.

Cognition Therapeutics currently has a consensus target price of $3.33, suggesting a potential upside of 197.62%. Dyadic International has a consensus target price of $3.00, suggesting a potential upside of 274.53%. Given Dyadic International's higher probable upside, analysts plainly believe Dyadic International is more favorable than Cognition Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cognition Therapeutics	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Cognition Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Cognition Therapeutics' return on equity of -72.68% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cognition Therapeutics	N/A	-72.68%	-53.07%
Dyadic International	-192.40%	-1,005.45%	-77.64%

Summary

Cognition Therapeutics beats Dyadic International on 9 of the 15 factors compared between the two stocks.

How does Dyadic International compare to Polaryx Therapeutics?

Dyadic International (NASDAQ:DYAI) and Polaryx Therapeutics (NASDAQ:PLYX) are both small-cap pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.

In the previous week, Dyadic International had 3 more articles in the media than Polaryx Therapeutics. MarketBeat recorded 4 mentions for Dyadic International and 1 mentions for Polaryx Therapeutics. Polaryx Therapeutics' average media sentiment score of 1.89 beat Dyadic International's score of 0.57 indicating that Polaryx Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Dyadic International	Positive
Polaryx Therapeutics	Very Positive

Dyadic International currently has a consensus price target of $3.00, indicating a potential upside of 274.53%. Polaryx Therapeutics has a consensus price target of $10.00, indicating a potential upside of 316.67%. Given Polaryx Therapeutics' higher possible upside, analysts clearly believe Polaryx Therapeutics is more favorable than Dyadic International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Dyadic International	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Polaryx Therapeutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Polaryx Therapeutics has lower revenue, but higher earnings than Dyadic International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Dyadic International	$3.09M	9.45	-$7.36M	-$0.23	N/A
Polaryx Therapeutics	N/A	N/A	N/A	N/A	N/A

Polaryx Therapeutics has a net margin of 0.00% compared to Dyadic International's net margin of -192.40%. Polaryx Therapeutics' return on equity of 0.00% beat Dyadic International's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Dyadic International	-192.40%	-1,005.45%	-77.64%
Polaryx Therapeutics	N/A	N/A	N/A

28.0% of Dyadic International shares are held by institutional investors. 20.9% of Dyadic International shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Dyadic International beats Polaryx Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Dyadic International News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DYAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

DYAI vs. The Competition

Export

Metric	Dyadic International	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$27M	$3.55B	$6.70B	$12.22B
Dividend Yield	N/A	2.25%	2.67%	6.13%
P/E Ratio	-3.48	21.56	25.76	24.17
Price / Sales	9.45	334.67	559.68	101.60
Price / Cash	N/A	137.38	46.99	54.37
Price / Book	26.70	8.34	10.77	6.35
Net Income	-$7.36M	$23.91M	$3.57B	$337.63M
7 Day Performance	2.43%	3.38%	2.15%	0.06%
1 Month Performance	5.41%	1.51%	1.06%	-0.15%
1 Year Performance	-19.81%	65.14%	34.16%	27.55%

Dyadic International Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
DYAI Dyadic International	3.0487 of 5 stars	$0.80 +8.1%	$3.00 +274.5%	-19.5%	$27M	$3.09M	N/A	7	News Coverage Analyst Forecast Short Interest Decrease Gap Up
COYA Coya Therapeutics	2.3801 of 5 stars	$4.82 -1.4%	$15.33 +218.1%	-6.8%	$114.71M	$7.95M	N/A	6	News Coverage
PYXS Pyxis Oncology	2.47 of 5 stars	$1.75 +0.6%	$6.83 +290.5%	+134.7%	$110.24M	$13.86M	N/A	60	News Coverage
CUE Cue Biopharma	0.5496 of 5 stars	$23.89 -7.4%	N/A	-96.4%	$108.37M	$27.47M	N/A	60	Positive News
CGTX Cognition Therapeutics	3.9726 of 5 stars	$1.26 +4.1%	$3.33 +164.6%	+245.1%	$108.29M	N/A	N/A	20	Analyst Forecast Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:DYAI) was last updated on 6/27/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Dyadic International (DYAI) Competitors

DYAI vs. COYA, PYXS, CUE, CGTX, and PLYX

How does Dyadic International compare to Coya Therapeutics?

Summary

How does Dyadic International compare to Pyxis Oncology?

Summary

How does Dyadic International compare to Cue Biopharma?

Summary

How does Dyadic International compare to Cognition Therapeutics?

Summary

How does Dyadic International compare to Polaryx Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Dyadic International (DYAI) Competitors

DYAI vs. COYA, PYXS, CUE, CGTX, and PLYX

How does Dyadic International compare to Coya Therapeutics?

Does the media refer more to DYAI or COYA?

Do insiders & institutionals hold more shares of DYAI or COYA?

Is DYAI or COYA more profitable?

Do analysts recommend DYAI or COYA?

Which has more risk and volatility, DYAI or COYA?

Which has better valuation & earnings, DYAI or COYA?

Summary

How does Dyadic International compare to Pyxis Oncology?

Does the media prefer PYXS or DYAI?

Do analysts rate PYXS or DYAI?

Is PYXS or DYAI more profitable?

Which has more risk and volatility, PYXS or DYAI?

Do insiders and institutionals have more ownership in PYXS or DYAI?

Which has preferable valuation and earnings, PYXS or DYAI?

Summary

How does Dyadic International compare to Cue Biopharma?

Do institutionals and insiders hold more shares of CUE or DYAI?

Do analysts recommend CUE or DYAI?

Which has higher earnings & valuation, CUE or DYAI?

Does the media favor CUE or DYAI?

Is CUE or DYAI more profitable?

Which has more volatility and risk, CUE or DYAI?

Summary

How does Dyadic International compare to Cognition Therapeutics?

Do institutionals and insiders have more ownership in CGTX or DYAI?

Does the media prefer CGTX or DYAI?

Which has stronger earnings & valuation, CGTX or DYAI?

Which has more risk & volatility, CGTX or DYAI?

Do analysts rate CGTX or DYAI?

Is CGTX or DYAI more profitable?

Summary

How does Dyadic International compare to Polaryx Therapeutics?

Does the media refer more to DYAI or PLYX?

Do analysts prefer DYAI or PLYX?

Which has higher earnings and valuation, DYAI or PLYX?

Is DYAI or PLYX more profitable?

Do institutionals & insiders believe in DYAI or PLYX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

DYAI vs. The Competition

Dyadic International Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools